397 related articles for article (PubMed ID: 35811662)
1. Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease.
Zeng Y; He H; An Z
Dis Markers; 2022; 2022():1254014. PubMed ID: 35811662
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments.
Ahn SB
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S150-S156. PubMed ID: 36696960
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
4. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
Wang L; Liu XE; Zhuang H
Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
[TBL] [Abstract][Full Text] [Related]
5. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
8. Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu IL; Brunt EM
World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076
[TBL] [Abstract][Full Text] [Related]
9. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
10. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Tsai E; Lee TP
Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
[TBL] [Abstract][Full Text] [Related]
12. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
Drescher HK; Weiskirchen S; Weiskirchen R
Cells; 2019 Aug; 8(8):. PubMed ID: 31394730
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.
Zhang JZ; Cai JJ; Yu Y; She ZG; Li H
Gene Expr; 2019 Nov; 19(3):187-198. PubMed ID: 31010457
[TBL] [Abstract][Full Text] [Related]
14. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
[TBL] [Abstract][Full Text] [Related]
15. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
16. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Sumida Y; Nakajima A; Itoh Y
World J Gastroenterol; 2014 Jan; 20(2):475-85. PubMed ID: 24574716
[TBL] [Abstract][Full Text] [Related]
17. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future.
Yu JH; Lee HA; Kim SU
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S136-S149. PubMed ID: 36503205
[TBL] [Abstract][Full Text] [Related]
19. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy.
Mikolasevic I; Domislovic V; Krznaric-Zrnic I; Krznaric Z; Virovic-Jukic L; Stojsavljevic S; Grgurevic I; Milic S; Vukoja I; Puz P; Aralica M; Hauser G
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208576
[No Abstract] [Full Text] [Related]
20. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
Papatheodoridi M; Cholongitas E
Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]